- cafead   Aug 09, 2024 at 11:32: AM
via Eli Lilly is still celebrating the FDA approval of its amyloid-directed Alzheimer's therapy Kisunla but has had less fortune with a candidate against tau, another well-established drug target for the disease.
article source
article source